Negative symptoms: Diagnosis, treatment and prognosis

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages 3-11

  Buchanan, R W ^a,b   Gold, J M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Clozapine; Deficit symptoms; Diagnosis; Negative symptoms; Premorbid adjustment; Prognosis; Schizophrenia

Indexed keywords

CLOZAPINE; CYCLOSERINE; GLYCINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

CONFERENCE PAPER; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 0029882559     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199605002-00002     Document Type: Conference Paper

References (80)

1. Abrams R, Taylor MA (1978) A rating scale for emotional blunting. Am J Psychiatry 135:226-229.
2. Addington J, Addington D (1993) Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci 18:18-23.
3. Andreasen NC (1982) Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 39:784-788.
4. Andreasen NC, Olsen S (1982) Negative v. positive schizophrenia: definition and validation. Arch Gen Psychiatry 39: 789-794.
5. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M (1995) Symptoms of schizophrenia. Arch Gen Psychiatry 52: 341-351.
6. 2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R64-766). Hum Psychopharmacol 5:225-231.
7. Biehl H, Maurer K, Jung E, Krumm B (1989) The WHO Psychological Impairments Rating Schedule (WHO/PIRS): II. Impairments in schizophrenics in cross-sectional and longitudinal perspective: the Mannheim experience in two independent samples. Br J Psychiatry 155:71-77.
8. Borison RL, Pathiraja AP, Diamond BI, Meibach RC (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28:213-218.
9. Breier A, Schreiber JL, Dyer J, Pickar D (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 48:239-246.
10. Breier A, Buchanan RW, Kirkpatrick B, et al. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26.
11. Brown KW, White T (1992) Syndromes of chronic schizophrenia and some clinical correlates. Br J Psychiatry 161: 317-322.
12. Buchanan RW, Carpenter WT (1994) Domains of psychopathology and approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 182:193-204.
13. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT (1990) Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry 147:290-294.
14. Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT (1994) Neuropsychological impairments in deficit vs. nondeficit forms of schizophrenia. Arch Gen Psychiatry 51:804-811.
15. Buchanan RW, Brandes M, Breier A (1996) Pharmacological strategies for treating negative symptoms. In The New Pharmacotherapy of Schizophrenia. Edited by Breier A. Washington DC: American Psychiatric Press, pp 179-204.
16. Bustillo J, Kirkpatrick, B, Buchanan RW (1995) Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia. Biol Psychiatry 38:64-67.
17. Carlsson CM (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
18. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:364-379.
19. Carpenter WT, Heinrichs DW, Alphs LD (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578-583.
20. Carpenter WT, Hanlon TE, Heinrichs DW, et al. (1990) Continuous vs. targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147:1138-1148.
21. 2 antagonist risperidone (R64-766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr Res 2:411-415.
22. Ceskova E, Svestka J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121-124.
23. Chouinard G, Jones B, Remington G, et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Psychopharmacology 13:25-40.
24. Claus A, Bollen J, De Cuyper H, et al. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatr Scand 85:295-305.
25. Conley R, Gounaris C, Tamminga C (1994) Clozapine response varies in deficit vs. nondeficit schizophrenic subjects. Biol Psychiatry 35:746-747.
26. Crow TJ (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11:471-486.
27. Daradkeh TK, Karim L (1994) Predictors of employment status of treated patients with DSM-III-R diagnosis: can logistic regression model find a solution? Int J Soc Psychiatry 40: 141-149.
28. Deister A, Marneros A (1994) Prognostic value of initial subtype in schizophrenic disorders. Schizophr Res 12:145-157.
29. Fenton WS, McGlashan TH (1991) Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 48:978-986.
30. Fenton WS, McGlashan TH (1992) Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 49:179-184.
31. Fenton WS, McGlashan TH (1994) Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 151:351-356.
32. Gelders YG, Heylen SLE, Bussche GV, Reyntjens AJM, Janssen PAJ (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23: 206-211.
33. Goff DC, Tsai G, Manoach DS, Coyle JE (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
34. Goldberg E (1985) Akinesia, tardive sysmentia, and frontal lobe disorder in schizophrenia. Schizophr Bull 11:255-263.
35. Gur RE, Mozley PD, Resnick SM, et al. (1991) Relations among clinical scales in schizophrenia. Am J Psychiatry 148:472-478.
36. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 88:395-402.
37. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
38. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1984) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
39. Johnstone ED, Frith CD, Lang FH, Owens DGC (1995) Determinants of the extremes of outcome in schizophrenia. Br J Psychiatry 167:604-609.
40. Jonsson SAT, Jonsson H (1992) Outcome in untreated schizophrenia: a search for symptoms and traits with prognostic meaning in patients admitted to a mental hospital in the preneuroleptic era. Acta Psychiatr Scand 85:313-320.
41. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-795.
42. Kay SR (1991) Positive and Negative Syndromes in Schizophrenia, Assessment and Research. New York: Brunner/Mazel.
43. Kay SR, Sevy S (1990) Pyramidical model of schizophrenia. Schizophr Bull 16:537-544.
44. Kay SR, Opler LA, Fishbein A (1992) Positive and Negative Syndrome Scale (PANSS) Rating Manual. Multihealth Systems Inc.
45. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter, WT (1989) The Schedule for the Deficit Syndrome: An instrument for research in schizophrenia. Psychiatry Res 30:119-124.
46. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT (1984) Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 182:452-455.
47. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K (1995) Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15 (suppl):45S-51S.
48. Kraepelin E (1919) Dementia Praecos and Paraphrenia. Edited by Barclay RE. Edinburgh: Livingston.
49. Krawiecka M, Goldberg D, Vaughan M (1977) A standardized psychiatric assessment for rating chronic psychotic patients. Acta Psychiatr Scand 55:299-308.
50. Lewine R, Fogg L, Meltzer H (1983) The development of scales for the assessment of positive and negative symptoms in schizophrenia. Schizophr Bull 9:368-376.
51. Leysen JE, Gommeren W, Eens A, de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670.
52. Liddle PF (1987) The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry 151:145-151.
53. Liddle PF, Barnes TRE (1990) Syndromes of chronic schizophrenia. Br J Psychiatry 157:558-561.
54. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSI (1992) Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160:179-186.
55. Lieberman JA, Safferman ZA, Pollack S, et al. (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151: 1744-1752.
56. Lysaker P, Bell M (1995) Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatr Scand 91: 205-208.
57. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
58. Mayerhoff DL, Loebel AD, Alvir JMJ, et al. (1994) The deficit state in first-episode schizophrenia. Am J Psychiatry 151: 1417-1422.
59. McGlashan TH, Fenton WS (1992) The positive-negative distinction in schizophrenia. Arch Gen Psychiatry 49:63-72.
60. Meco G, Bedini L, Bonifati V, Sonsini U (1989) Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo. Curr Ther Res 46:876-883.
61. Meltzer HY (1995) Clozapine: is another view valid? Am J Psychiatry 152:821-825.
62. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R64-766) in psychotic patients. Psychopharmacology 99:445-448.
63. Miller DD, Perry PJ, Cadorer RJ, Andreasen NC (1994) Clozapine's effect on negative symptoms in treatment refractory schizophrenics. Compr Psychiatry 35:8-13.
64. Minas IH, Stuart GW, Klimidis S, Jackson HJ, Singh BS, Copolov DL (1992) Positive and negative symptoms in the psychoses: multidimensional scaling of SAPS and SANS items. Schizophr Res 8:143-156.
65. Moller HJ, Pelzer E, Kissling W, Riehl T, Wernicke T (1991) Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry 24:185-189.
66. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245:45-49.
67. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
68. Opler LA, Albert D, Ramirez PM (1994) Psychopharmacologic treatment of negative schizophrenic symptoms. Compr Psychiatry 35:16-28.
69. Pakaslahti A (1992) Prediction of Working Disability in Schizophrenia. Helsinki: Social Insurance Institution.
70. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
71. Pickar D, Owen RR, Luman RE, Konicki PE, Gunierrez L, Rapaport MH (1992) Clinical and biological response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 49:345-353.
72. Pogue Geile MF (1989) The prognostic significance of negative symptoms in schizophrenia. Br J Psychiatry 155:123-127.
73. Pogue Geile MF, Harrow M (1984) Negative and positive symptoms in schizophrenia and depression: a followup. Schizophr Bull 10:371-387.
74. Pogue Geile MF, Harrow M (1985) Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull 11:427-439.
75. Ribeiro SCM, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF (1992) Clinical predictors of 1-year outcome in schizophrenia. Psychopathology 25:331-334.
76. Salokangas RKR, Stengard E (1990) Gender and short-term outcome in schizophrenia. Schizophr Res 3:333-345.
77. Strauss JS, Carpenter WT, Bartko JJ (1974) The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11:61-75.
78. Tandon R, Goldman R, DeQuardo JR, et al. (1993) Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 27:341-347.
79. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
80. Wing JK, Brown GW (1970) Institutionalism and Schizophrenia. A Comparative Study of Three Mental Hospitals. Cambridge: Cambridge Unversity Press.